# Vicore Pharma Holding AB

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Vicore Pharma Holding AB).

## Overview

Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases. The group operates through Vicore Pharma AB and Vicore Pharma US Inc., with its main office in Stockholm and a listed presence in Stockholm and the U.S.

## Products & services

• Development of buloxibutid for idiopathic pulmonary fibrosis
• Early-stage discovery of angiotensin II type 2 receptor agonists (ATRAGs)
• Preclinical and translational respiratory biology research
• In-house R&D services and scientific development support

- **Clinical-stage drug candidates** (70%) — Investigational therapies advanced through preclinical and clinical development.
- **Discovery research** (20%) — Early-stage programs and target discovery around ATRAG-based biology.
- **Research support and internal services** (10%) — Scientific, development, and business support activities within the group.

- Development of buloxibutid for idiopathic pulmonary fibrosis
- Early-stage discovery of angiotensin II type 2 receptor agonists (ATRAGs)
- Preclinical and translational respiratory biology research
- In-house R&D services and scientific development support

## Customers

Vicore is not a traditional commercial drug seller; its direct counterparties are primarily hospitals, clinical research sites, CROs, and laboratory partners that support the development program. Ultimate beneficiaries are patients and physicians in severe respiratory and fibrotic diseases, while future commercial buyers would be specialty prescribers and healthcare systems if a candidate is approved.

- **Clinical research network** (primary) — Hospitals, clinics, and investigators participating in Vicore-sponsored trials and patient recruitment.
- **CRO and service partners** (primary) — External partners providing trial management, scientific services, and development execution.
- **Research collaborators** (secondary) — Academic and industry partners contributing to discovery and translational science.
- **Future specialty prescribers** (emerging) — Pulmonologists and specialty centers that would use an approved therapy in severe lung disease.

- Clinical trial sites that enroll patients in Vicore studies
- CROs and service providers supporting development work
- Laboratories and research collaborators in respiratory biology
- Future specialty prescribers treating fibrotic lung disease
- Healthcare systems and payers in approved indications

## Geography

Vicore is headquartered in Stockholm, Sweden, and the group includes a U.S. subsidiary for local development and business support. Its operating footprint is tied to clinical and research activity rather than broad commercial manufacturing, so geography mainly reflects where trials, scientific work, and corporate functions are organized.

- Headquartered in Stockholm, Sweden
- Operates through Swedish parent and U.S. subsidiary
- R&D and clinical activity are the main geographic drivers
- U.S. presence supports development and future market access
- No country revenue breakdown was disclosed in the excerpts

## Strategy

Vicore's strategy centers on advancing buloxibutid through clinical development while building a broader pipeline around ATRAG biology. The company also expands its research foundation and external development capabilities to support later-stage value creation and potential partnering options.

- **Advance buloxibutid in idiopathic pulmonary fibrosis** (short-term) — Clinical progress is the main value driver for a development-stage biotech company.
- **Expand the early-stage ATRAG pipeline** (medium-term) — A broader pipeline reduces dependence on one asset and creates long-term platform value.
- **Strengthen scientific and translational capabilities** (medium-term) — Deeper biology and discovery capabilities support better target selection and differentiation.

- Advance buloxibutid through clinical proof-of-concept
- Build a broader ATRAG pipeline from early discovery
- Strengthen translational science in respiratory disease
- Use external research and development partners efficiently
- Preserve optionality for partnering or future commercialization

## Risks

Vicore's business is exposed to the high failure rate of pharmaceutical R&D, where most projects do not reach approval and clinical programs can be delayed by efficacy, safety, enrollment, or manufacturing issues. As a development-stage biotech, it also depends on continued funding and execution across a small number of programs, which makes setbacks in any one asset material.

- **Clinical trial failure or delay** [critical] — The lead asset must show efficacy and tolerability in trials before value can be realized.
- **Patient recruitment and site execution risk** [high] — Enrollment and trial conduct can slow development timelines and increase costs.
- **Financing and capital intensity** [high] — R&D-heavy biotech models consume cash before commercialization and may need repeated funding.
- **Pipeline concentration** [high] — A limited number of programs makes the company vulnerable to setbacks in one asset.

- Clinical failure risk if buloxibutid lacks efficacy or safety
- Patient recruitment and trial timing can delay readouts
- R&D spending and capital needs can rise faster than planned
- Dependence on a small pipeline increases concentration risk
- Drug development has a high historical attrition rate

## Accounting

The group’s results are dominated by R&D expense recognition, accruals, and intercompany support charges rather than commercial revenue. Judgments around prepaid expenses, accrued R&D, and capitalization versus expensing can materially affect period comparability, while any future licensing or milestone income would require careful revenue recognition assessment.

- **R&D accruals and prepaid expenses** — Can change expense timing and balance sheet presentation without altering cash flow.
- **Intercompany service fees** — Affects consolidation eliminations and local entity results.
- **Shareholder contributions** — Impacts equity financing presentation rather than operating revenue.
- **R&D expense recognition** — Shapes reported losses and makes period-to-period comparability dependent on trial timing.

- R&D accruals and prepaid expense judgments affect period expenses
- Intercompany support fees influence parent and subsidiary results
- Unconditional shareholder contributions affect equity and liquidity
- Future licensing income would require IFRS 15 assessment
- No commercial product revenue means results are cost-driven

---

*Last updated: 2026-09-28T12:18:37.179344+00:00*